Moderna Inc said on Monday that its Omicron-adapted vaccines produced a better immune response against the BA.4/5 subvariants in a mid- to late-stage study, when given as a booster dose, compared to its original shot.
The data show that Moderna’s two Omicron-adapted shots, mRNA-1273.214 and mRNA-1273.222, produced a greater antibody response against the BA.4/5 subvariants than its original shot in vaccinated and boosted adults, the company said.
Moderna, however, said neutralizing antibody response levels fell nearly 5-fold against the emerging BQ.1.1 subvariant compared to BA.4/5, in an analysis of about 40 participants, although virus-neutralizing activity was still maintained “solid”.
FDA AUTHORIZES UPDATED TYPES OF COVID-19 BOOST ORIGINATING OMICRON VARIANT
CLICK HERE TO GET THE FOX NEWS APP
Rival Pfizer Inc and its German partner BioNTech SE said earlier this month that its Omicron-adapted shot targeting the BA.4/5 subvariants produced a stronger antibody response in older adults than the original shot after one month.
Based on data from preclinical studies, the Omicron customized shots made by Moderna and Pfizer have already been approved in the United States for both adults and children up to five years of age. According to government data, nearly 31.4 million Americans had received the updated vaccine as of November. 9, with about 5.1 million vaccinated last week.